The Journal of Practical Medicine >
Clinical application progress of immunization and targeted therapy for Hepatocellular Carcinoma in special populations
Received date: 2023-08-25
Online published: 2024-04-08
Hepatocellular carcinoma （HCC） has become the second leading cause of cancer-related death worldwide， ranking 6th among all tumors. Due to the lack of obvious early symptoms， most patients are diagnosed in the advanced stage， and the clinical benefits of surgical resection and hepatic artery chemoembolization and radiofrequency ablation are very limited. In recent years， the advent of immune-targeted therapies has revolutionized the systemic and systemic treatment of patients with advanced HCC， however， there is a lack of strong clinical evidence on the safety and efficacy of immune and targeted therapies for special populations， including patients with human immunodeficiency virus （HIV） infection， active autoimmune disease， decompensated cirrhosis （Child B or C）， patients with diabetes-associated metabolic syndrome， patients with portal hypertension， vascular invasion， or portal vein thrombosis （PVT）， and patients with liver transplantation （LT）.This article reviews the current research progress of immune and targeted drugs in special populations.
Fazhu FEI , Jiajun LU , Shuai ZHANG , Hao LI , Bin REN . Clinical application progress of immunization and targeted therapy for Hepatocellular Carcinoma in special populations[J]. The Journal of Practical Medicine, 2024 , 40(6) : 738 -742 . DOI: 10.3969/j.issn.1006-5725.2024.06.002
| 1 | XIA C， DONG X， LI H， et al. Cancer statistics in China and United States， 2022： profiles， trends， and determinants ［J］ . Chin Med J （Engl）， 2022，135（5）：584-590. doi:10.1097/cm9.0000000000002108 |
| 2 | WEN N， CAI Y， LI F， et al. The clinical management of hepatocellular carcinoma worldwide： A concise review and comparison of current guidelines： 2022 update［J］. Biosci Trends， 2022，16（1）：20-30. doi:10.5582/bst.2022.01061 |
| 3 | LIOVET J M， RICCI S， MAZZAFERRO V，et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med， 2008，359（4）：378-390. doi:10.1056/nejmoa0708857 |
| 4 | WANG L， WANG F S. Clinical immunology and immunotherapy for hepatocellular carcinoma： current progress and challenges［J］. Hepatol Int， 2019，13（5）：521-533. doi:10.1007/s12072-019-09967-y |
| 5 | HAO X， SUN G， ZHANG Y， et al. Targeting Immune Cells in the Tumor Microenvironment of HCC： New Opportunities and Challenges［J］. Front Cell Dev Biol， 2021，9：775462. doi:10.3389/fcell.2021.775462 |
| 6 | SANGRO B， GOMEZ-MARTIN C， DE LA MATA M， et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C［J］. J Hepatol， 2013，59（1）：81-88. doi:10.1016/j.jhep.2013.02.022 |
| 7 | RINI B I， PLIMACK E R， STUS V， et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma［J］. N Engl J Med， 2019，380（12）：1116-1127. doi:10.1056/nejmoa1816714 |
| 8 | El-KHOUEIRY A B， SANGRO B， YAU T， et al. Nivolumab in patients with advanced hepatocellular carcinoma （CheckMate 040）： an open-label， non-comparative， phase 1/2 dose escalation and expansion trial［J］. Lancet， 2017，389（10088）：2492-2502. doi:10.1016/s0140-6736(17)31046-2 |
| 9 | MERCHANTE N， IBARRA S， REVOLLO B， et al. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients［J］. AIDS， 2017，31（1）：89-95. doi:10.1097/qad.0000000000001293 |
| 10 | LYTHGOE M P， JULVE M， PINATO D J， et al. Regorafenib therapy for hepatocellular carcinoma in a HIV‐1‐infected patient： A case report［J］. Liver Cancer International， 2020，1（2）： 51-54. doi:10.1002/lci2.15 |
| 11 | RIGOPOULOU E I， DALEKOS G N. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases［J］. Cancers （Basel）， 2021，13（5）：1023. doi:10.3390/cancers13051023 |
| 12 | HAANEN JBAG， CARBONNEL F， ROBERT C， et al. Management of toxicities from immunotherapy： ESMO Clinical Practice Guidelines for diagnosis， treatment and follow-up［J］. Ann Oncol， 2017，28（）：iv119-iv142. doi:10.1093/annonc/mdx225 |
| 13 | ZHANG D， HART J， DING X， et al. Histologic patterns of liver injury induced by anti-PD-1 therapy［J］. Gastroenterol Rep （Oxf）， 2019，8（1）：50-55. doi:10.1093/gastro/goz044 |
| 14 | 赵继伟，曾志芬，曾红华，等.程序性细胞死亡蛋白-1抑制剂治疗晚期肝癌致多系统不良反应1例的诊疗经验［J］.实用医学杂志，2022，38（12）：1569-1572. |
| 15 | DANLOS F X， VOISIN A L， DYEVRE V， et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease［J］. Eur J Cancer， 2018，91：21-29. doi:10.1016/j.ejca.2017.12.008 |
| 16 | HUANG P H， YU J， CHU Y Y， et al. Child-Pugh Score and ABCG2-rs2231142 Genotype Independently Predict Survival in Advanced Hepatoma Patients Treated with Sorafenib［J］. J Clin Med， 2022，11（9）：2550. doi:10.3390/jcm11092550 |
| 17 | WONG J S L， KWOK G G W， TANG V， et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors［J］. J Immunother Cancer， 2021，9（2）：e001945. doi:10.1136/jitc-2020-001945 |
| 18 | YOUNOSSI Z M， GOLABI P， PAIK J M， et al. The global epidemiology of nonalcoholic fatty liver disease （NAFLD） and nonalcoholic steatohepatitis （NASH）： a systematic review［J］. Hepatology， 2023，77（4）：1335-1347. doi:10.1097/hep.0000000000000004 |
| 19 | OURA K， MORISHITA A， TANI J， et al. Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma［J］. J Hepatocell Carcinoma， 2022，9：1279-1298. doi:10.2147/jhc.s392051 |
| 20 | BRUIX J， RAOUL J L， SHERMAN M， et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma： subanalyses of a phase Ⅲ trial［J］. J Hepatol， 2012，57（4）：821-829. doi:10.1016/j.jhep.2012.06.014 |
| 21 | CASADEI GARDINI A， FALOPPI L， DE MATTEIS S， et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib： Validation study and biological rationale［J］. Eur J Cancer， 2017，86：106-114. doi:10.1016/j.ejca.2017.09.003 |
| 22 | CORTELLINI A， BERSANELLI M， BUTI S， et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors： when overweight becomes favorable［J］. J Immunother Cancer， 2019，7（1）：1-11. doi:10.1186/s40425-019-0527-y |
| 23 | DE MATTOS ? Z， TERRA C， FARIAS A Q， et al. Primary prophylaxis of variceal bleeding in patients with cirrhosis： A comparison of different strategies［J］. World J Gastrointest Endosc， 2021，13（12）：628-637. doi:10.4253/wjge.v13.i12.628 |
| 24 | PINTER M， SIEGHART W， REIBERGER T， et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study［J］. Aliment Pharmacol Ther， 2012，35（1）：83-91. doi:10.1111/j.1365-2036.2011.04896.x |
| 25 | CHENG A L， QIN S， IKEDA M， et al. Updated efficacy and safety data from IMbrave150： Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma［J］. J Hepatol， 2022，76（4）：862-873. doi:10.1016/j.jhep.2021.11.030 |
| 26 | LARREY E， CAMPION B， EVAIN M， et al. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC［J］. Liver Int， 2022，42（12）：2843-2854. doi:10.1111/liv.15458 |
| 27 | QADAN M， KOTHARY N， SANGRO B， et al. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis［J］. Am Soc Clin Oncol Educ Book， 2020，40：174-185. doi:10.1200/edbk_280811 |
| 28 | GALLE P R， FORNER A， LLOVET J M， et al. EASL clinical practice guidelines： management of hepatocellular carcinoma［J］. J Hepatol， 2018，69（1）：182-236. doi:10.1016/j.jhep.2018.03.019 |
| 29 | TSAI H M， HAN M Z， LIN Y J， et al. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis［J］. Cancer Immunol Immunother， 2021，70（7）：1929-1937. doi:10.1007/s00262-020-02845-9 |
| 30 | WONG T H， HO C M， HSU H H， et al. Delayed Hepatocellular Carcinoma Recurrence After Liver Transplantation： Comprehensive Clinical Characterization of Case Series［J］. J Hepatocell Carcinoma， 2022，9：1081-1091. doi:10.2147/jhc.s383474 |
| 31 | DELYON J， ZUBER J， DORENT R， et al. Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge［J］. Transplantation， 2021，105（1）：67-78. doi:10.1097/tp.0000000000003292 |
| 32 | AU K P， CHOK K S H. Immunotherapy after liver transplantation： Where are we now？［J］. World J Gastrointest Surg， 2021，13（10）：1267-1278. doi:10.4240/wjgs.v13.i10.1267 |
/
| 〈 |
|
〉 |